Curadh is pioneering the eradication of solid tumors through the new science of molecularly targeted radiation
About us
Patients, their families and loved ones are waiting for skilled researchers to cure cancer.
CuradhMTR has a highly experienced team focused on the new field of molecularly targeted radiation (MTR), with experts in all stages of oncology drug development and a track record of successful MTR development.
Explore our latest news and insights
Alpha Fusion, Inc. (“Alpha Fusion”) and Curadh MTR Inc. (“Curadh”) announced plans to enter a strategic partnership
Alpha Fusion, Inc. (“Alpha Fusion”) and Curadh MTR Inc. (“Curadh”) announced plans to enter a strategic partnership, including a Joint Venture to broadly advance the global development of Astatine-211 (At-211) based radiopharmaceuticals. The collaboration combines Alpha Fusion’s leading role in At-211 drug discovery and early clinical work in Japan, with Curadh’s global expertise in radiopharmaceutical development.
Curadh MTR debuts at BioEquity, Europe with New CEO and Expanded Leadership Team
Curadh MTR Inc., leading the development of 2nd generation radiopharmaceuticals, designed to eradicate solid tumours, today announced its emergence from stealth with the appointment of Glenn Kazo as Chief Executive Officer and Amrik Basran as Chief Scientific Officer.
Northstar Medical Radioisotopes and Curadh MTR Enter Strategic Collaboration Agreement for Development and Production of Actinium-225 (Ac-225)-based Therapeutic Radiopharmaceuticals for Treatment of Primary and Metastatic Solid Tumors
NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, and Curadh MTR Inc. (Curadh), a global MTR-focused clinical, research and advisory organization, today announced a long-term strategic collaboration to develop and produce novel radiopharmaceuticals for the diagnosis and treatment of solid tumor cancers.